Anteris Technologies Reports Q1 Revenue $494K, EPS ($0.28); Advances Pivotal Clinical Trial & Secures Medicare Coverage
AVR has more than doubled off its 52-week low of $2.85.
Summary
Anteris Technologies Global Corp. reported Q1 2026 results, showing $494K in revenue and a diluted loss per share of ($0.28). While revenue decreased 11.2% year-over-year and net loss slightly widened to ($22.9M), the diluted EPS improved significantly from ($0.61) in the prior year. Crucially for this Life Sciences company, the report highlighted substantial operational progress, including the launch of the PARADIGM pivotal global randomized trial in Europe, activation of U.S. sites following FDA IDE approval, and securing U.S. Medicare coverage for trial procedures. For a development-stage biotech, these clinical and regulatory advancements are paramount, often outweighing early financial metrics. Traders will focus on continued trial execution and further regulatory milestones as key catalysts.
At the time of this announcement, AVR was trading at $6.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $651.5M. The 52-week trading range was $2.85 to $6.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.